Published in PLoS One on February 23, 2015
Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol (2015) 0.93
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res (2015) 0.89
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget (2015) 0.84
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas. Metabolites (2017) 0.82
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res (2016) 0.81
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin (2016) 0.80
IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage. Cell Mol Neurobiol (2016) 0.76
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Mol Cancer Res (2017) 0.75
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget (2016) 0.75
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Front Oncol (2016) 0.75
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro Oncol (2016) 0.75
MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. Top Magn Reson Imaging (2016) 0.75
Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1. Mol Cell Oncol (2015) 0.75
MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. Biomed Res Int (2017) 0.75
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res (2012) 9.21
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
The definition of primary and secondary glioblastoma. Clin Cancer Res (2012) 3.84
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J (1990) 3.44
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med (2012) 3.30
Metabolic profiles of cancer cells. Nat Rev Cancer (2004) 3.21
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet (2011) 2.62
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med (2013) 2.27
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med (2012) 2.12
Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem (2007) 1.99
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol (2011) 1.67
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med (2012) 1.67
Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto Calif) (2008) 1.63
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res (2012) 1.36
Baseline correction for NMR spectroscopic metabolomics data analysis. BMC Bioinformatics (2008) 1.35
Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun (2013) 1.26
Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer (2001) 1.11
1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed (2009) 1.11
The biological synthesis of phospholipids. Can J Biochem Physiol (1956) 1.05
Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol (2013) 1.04
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. ACS Chem Biol (2010) 1.01
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res (2014) 0.99
Descriptive review of current NMR-based metabolomic data analysis packages. Prog Nucl Magn Reson Spectrosc (2011) 0.96
1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines. NMR Biomed (2007) 0.95
A novel R-package graphic user interface for the analysis of metabonomic profiles. BMC Bioinformatics (2009) 0.95
Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS One (2011) 0.89